Compare ImmunityBio Inc. Common Stock (IBRX) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10.25 (market cap $10.50B), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| IBRX | KYMR | |
|---|---|---|
Market Cap | $10.50B | $8.88B |
Volume | 30,068,214 | 1,028,790 |
Sector | Health | Health |
52-Week High | $11.55 | $127.31 |
52-Week Low | $1.98 | $55.80 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.96B | $8.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
